Oncology platform Thyme Care raised $125 million in Series E funding, doubling its valuation to over $2 billion. The profitable startup is establishing a parent company, Thyme Companies, to launch new ventures targeting cancer drug affordability and clinical trial access.
FireBrief
FireBrief